Benzinga · Oct 12, 2026
BTIG Maintains Buy on AtriCure, Raises Price Target to $63
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.
NASDAQ · ATRC
AtriCure, Inc.
Healthcare · Medical - Instruments & Supplies
$61.25
Down-$1.23 (-1.97%)
Updated Oct 31, 2026, 5:24 PM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.06B
- P/E ratio
- -68.62
- Dividend yield
- 0.00%
- 52-week range
- $25.36 – $63.00
- Volume
- 967.36K
- Avg. volume
- 515.68K
Price performance · ATRC
ATRC price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ATRC closed at $61.25 after 21 trading sessions, up 11.08% for the selected period.
- Last close
- $61.25
- Period change
- +11.08%
- Period low
- $52.84
- Period high
- $62.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $62.405 | $62.405 | $59.70 | $61.25 | 967.36K |
| Oct 29, 2026 | $61.71 | $62.86 | $61.69 | $62.48 | 702.37K |
| Oct 28, 2026 | $61.08 | $62.9999 | $61.06 | $61.42 | 647.55K |
| Oct 27, 2026 | $60.855 | $61.78 | $60.08 | $61.51 | 783.2K |
| Oct 26, 2026 | $59.35 | $61.18 | $58.845 | $61.08 | 816.23K |
| Oct 23, 2026 | $58.94 | $59.555 | $58.53 | $58.97 | 497.16K |
| Oct 22, 2026 | $57.76 | $59.54 | $57.76 | $59.30 | 498.18K |
| Oct 21, 2026 | $57.73 | $59.2856 | $57.1313 | $57.67 | 566.33K |
| Oct 20, 2026 | $55.64 | $58.195 | $55.64 | $57.67 | 446.38K |
| Oct 19, 2026 | $55.75 | $56.58 | $55.16 | $55.53 | 607.22K |
| Oct 16, 2026 | $57.98 | $58.31 | $55.90 | $56.07 | 648.35K |
| Oct 15, 2026 | $57.83 | $58.44 | $56.27 | $57.78 | 850.92K |
| Oct 14, 2026 | $56.13 | $57.89 | $55.84 | $57.30 | 799.31K |
| Oct 13, 2026 | $57.60 | $57.98 | $56.39 | $56.87 | 596.1K |
| Oct 12, 2026 | $56.29 | $57.35 | $55.67 | $57.28 | 645.6K |
| Oct 9, 2026 | $53.14 | $55.89 | $52.435 | $55.81 | 712.51K |
| Oct 8, 2026 | $53.07 | $53.46 | $51.63 | $52.84 | 595.66K |
| Oct 7, 2026 | $53.35 | $54.88 | $52.98 | $53.31 | 753.53K |
| Oct 6, 2026 | $55.97 | $56.58 | $53.43 | $53.68 | 863.66K |
| Oct 5, 2026 | $54.14 | $56.60 | $53.86 | $56.37 | 1.1M |
| Oct 2, 2026 | $52.51 | $55.25 | $52.00 | $55.14 | 1.62M |
Latest ATRC news
The latest Smart Investors Daily articles mentioning ATRC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ATRC research
Overview
Company profile and research snapshot.
Company profile
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $59.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Citizens | Market Outperform | — |
| Oct 12, 2026 | BTIG | Buy | — |
| Oct 2, 2026 | Freedom Capital Markets | Hold | — |
| Sep 2, 2026 | Needham | Buy | — |
| Aug 27, 2026 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 5, 2026
AtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And Risks
AtriCure’s fair value price target has shifted from about US$51.67 to about US$54.89, which reflects modest fine tuning in analyst models rather than a wholesale reset. Recent research ties these adjustments to how analysts balance new procedural drivers such as the STS Quality Metric and future BoX-NoAF POAF data against ongoing clinical and execution risks, as well as the tighter cluster of targets around the current valuation range. Read on to see how to track this evolving analyst...
Benzinga · Oct 2, 2026
Freedom Capital Markets Downgrades AtriCure to Hold, Raises Price Target to $57
Freedom Capital Markets analyst Keith Hinton downgrades AtriCure (NASDAQ:ATRC) from Buy to Hold and raises the price target from $43 to $57.
Benzinga · Feb 18, 2026
Demystifying AtriCure: Insights From 6 Analyst Reviews
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
